
aTyr Pharma, Inc.
- Jurisdiction
United States - ISIN
US0021202025 (LIFE )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Read full profile
Fundamentals
- Net revenue
-€3.98M - Gross margin
58.5% - EBIT
-€66.94M - EBIT margin
1,681.1% - Net income
-€64.42M - Net margin
1,618.0%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: March 14, 2024 (Q4 2023)